7th Translational Research Conference
Multiple Myeloma
October 4-6, 2024 - Mandelieu, France
Chairpersons : Hartmut Goldschmidt, Martin Kaiser, Suzanne Lentzsch

Friday, October 4th, 2024

08:30–08:40 Welcome

SESSION I – MGUS
Chair: Bruno Paiva (Pamplona)

08:40-08:45	Introduction	Bruno Paiva (Pamplona)
08:45-09:00	Do we need to screen for MGUS?	Sigrun Thorsteinsdottir (Reykjavik)
09:00-09:05	*Discussion*	
09:05-09:20	Definition and clinical significance of MGUS-like phenotype	Bruno Paiva (Pamplona)
09:20-09:25	*Discussion*	
09:25-09:40	Can the immunenvironment affect MGUS?	Madhav Dhodapkar (Atlanta)
09:40-09:45	*Discussion*	
09:45-09:52	**Selected brief oral communication** *A four-clinical variables based score to identify MGUS patients at risk of progression: a retrospective single-center study with 10 years follow up*	*Alessandra Romano (Catania)*
09:52-09:55	Discussion	
09:55-10:25	*Panel discussion*	

10:25-10:55 Coffee break and poster viewing

SESSION II – Smouldering myeloma
Chairs: Martin Kaiser (London), Shaji Kumar (Rochester)

10:55-11:00	Introduction	Martin Kaiser (London), Shaji Kumar (Rochester)
11:00-11:15	Can genomics tell us who to treat with SMM?	Ola Landgren (Miami)
11:15-11:20	*Discussion*	
11:20-11:35	When to start treatment for SMM	Francesca Gay (Turin)
11:35-11:40	*Discussion*	
11:40-11:55	Smouldering multiple myeloma: cancer or condition?	Sigrun Thorsteinsdottir (Reykjavik)

11:55-12:00	*Discussion*	
12:00-12:07	**Selected brief oral communication** *Geno-transcriptomic profiling of Polyclonal Plasma Cells uncovers a unique single-cell phenotype in plasma cell dyscrasias with clinical implications*	*Antonio Matera (Milan)*
12:07-12:10	*Discussion*	
12:10-12:40	*Panel discussion*	
12:40-14:10	***Lunch***	

SESSION III – Characterising multiple myeloma
Chair: Suzanne Lentzsch (New York)

14:10-14:15	Introduction	Suzanne Lentzsch (New York)
14:15-14:30	Clonal evolution in multiple myeloma	Eileen Boyle (Ellwood City)
14:30-14:35	*Discussion*	
14:35-14:50	Imaging in plasma cell dyscrasias: How, when and how often?	Jens Hillengass (Buffalo)
14:50-14:55	*Discussion*	
14:55-15:10	Immune suppression and bone disease	Suzanne Lentzsch (New York)
15:10-15:15	*Discussion*	
15:15-15:22	**Selected brief oral communication** *Hypersialylation influences PFS and achievement of sustained MRD negativity in transplant eligible newly diagnosed MM patients treated with quadruplet induction, transplant, consolidation and maintenance: an analysis of the CASSIOPEIA study.*	*Michael O'Dwyer (Galway)*
15:22-15:25	*Discussion*	
15:25-15:55	*Panel discussion*	
15:55-16:25	***Coffee break and poster viewing***	

SESSION IV – Newly diagnosed fit multiple myeloma patients
Chair: Hartmut Goldschmidt (Heidelberg)

16:25-16:30	Introduction	Hartmut Goldschmidt (Heidelberg)
16:30-16:45	High-risk newly diagnosed multiple myeloma	Martin Kaiser (London)
16:45-16:50	*Discussion*	
16:50-17:05	How to treat and maintain standard-risk multiple myeloma	Hartmut Goldschmidt (Heidelberg)
17:05-17:10	*Discussion*	
17:10-17:25	Is there still a role for ASCT?	Mohammad Mohty (Paris)
17:25-17:30	*Discussion*	
17:30-17:37	**Selected brief oral communication** *Response-adapted treatment cessation post quadruplets*	*Luciano Costa (Birmingham, AL)*

(QUADs) + ASCT in newly diagnosed multiple myeloma (NDMM): defining the optimal endpoint
17:37-17:40 *Discussion*

17:40-18:10 *Panel discussion*

18:10-19:30 **Mentored Poster Walks and Welcome Get Together stand up buffet dinner**
Poster Walk leaders: Jens Hillengass (Buffalo), Charlotte Pawlyn (London)

Saturday, October 5th, 2024

08:00-09:00 **3 Simultaneous Meet the Expert sessions (non-clinical)**

1. How to apply NGS ? — Pieter Sonneveld (Rotterdam)
2. Novel antigens for immunotherapy — Wee Joo Chng (Singapore)
3. Myeloma mice models — Karin Vanderkerken (Brussels)

09:10-10:10 **SATELLITE SYMPOSIUM:**
How to sequence BCMA-directed therapies in early relapsed/ refractory multiple myeloma
Chair: Mohamad Mohty (Paris)
Speakers: Martin Kaiser (London), Mohamad Mohty (Paris), Rakesh Popat (London)

This independent symposium is organized by SES on behalf of the Multiple Myeloma Hub and funded by GSK. GSK are allowed no influence on the content of this symposium.

10:10-10:40 ***Coffee break and poster viewing***

SESSION V – Newly-diagnosed unfit myeloma patients
Chair: Hermann Einsele (Würzburg)

10:40-10:45 Introduction — Hermann Einsele (Würzburg)

10:45-11:00 Who is the frail patient? — Charlotte Pawlyn (London)
11:00-11:05 *Discussion*

11:05-11:20 BITEs or CAR-T cells in older patients? — Hermann Einsele (Würzburg)
11:20-11:25 *Discussion*

11:25-11:40 Indefinite treatment for frail patients? — Shaji Kumar (Rochester)
11:40-11:45 *Discussion*

11:45-11:52 **Selected brief oral communication** — *Jana Balcarkova (Olomouc)*
Molecular profiling of cell-free and genomic DNA in multiple myeloma patients
11:52-11:55 *Discussion*

11:55-12:25 *Panel discussion*

12:25-13:55 ***Lunch***

SESSION VI – Personalising treatment
Chair: Noopur Raje (Boston)

13:55-14:00	Introduction	Noopur Raje (Boston)
14:00-14:15	Targeting signalling pathways and translocations	Marc Raab (Heidelberg)
14:15-14:20	*Discussion*	
14:20-14:35	MRD-driven treatment of multiple myeloma	Luciano Costa (Birmingham, AL)
14:35-14:40	*Discussion*	
14:40-14:55	Risk of infection and the era of bispecific antibodies and CAR T cells	Noopur Raje (Boston)
14:55-15:00	*Discussion*	
15:00-15:07	**Selected brief oral communication** *Nuclear respiratory factor 1 (NRF1) sustains the development, progression and resistance of multiple myeloma*	*Giacomo Corleone (Rome)*
15:07-15:10	*Discussion*	
15:10-15:40	*Panel discussion*	
15:40-16:10	***Coffee break and poster viewing***	

SESSION VII – Triplets vs immunotherapy in early lines of treatment
Chair: Meral Beksac (Ankara)

16:10-16:15	Introduction	Meral Beksac (Ankara)
16:15-16:30	BCMA-TCE will win?	Philippe Moreau (Nantes)
16:30-16:35	*Discussion*	
16:35-16:50	BCMA-CAR will win?	Paula Rodriguez-Otero (Pamplona)
16:50-16:55	*Discussion*	
16:55-17:10	Novel triplets will win?	Ajay Nooka (Atlanta)
17:10-17:15	*Discussion*	
17:15-17:22	**Selected brief oral communication** *CAR-T cells influence immune capacity of endogenous CD8+ T cells*	*Kayleen Shi (Boston)*
17:22-17:25	*Discussion*	
17:25-17:55	*Panel discussion*	

Sunday, October 6th, 2024

07:30-08:30 3 Simultaneous Breakfast Meet the Expert Sessions (Clinical)

1. When to start treatment in multiple myeloma? — Meral Beksac (Ankara)
2. How do I treat high-risk patients? — Martin Kaiser (London)
3. How do I image and treat multiple myeloma bone disease? — Evangelos Terpos (Athens)

SESSION VIII – Late relapse
Chair: Luciano Costa (Birmingham, AL)

08:35-08:40	Introduction	Luciano Costa (Birmingham, AL)
08:40-08:55	Non-Immunotherapeutic approaches for late relapse	Rakesh Popat (London)
08:55-09:00	*Discussion*	
09:00-09:15	Non BCMA-TCE for late relapse	Paula Rodriguez-Otero (Pamplona)
09:15-09:20	*Discussion*	
09:20-09:35	CARs beyond BCMA for late relapse	Sham Mailankody (New York)
09:35-09:40	*Discussion*	
09:40-09:47	**Selected brief oral communication** *PSMD10 in multiple myeloma: insights into protein interactions and oncogenic mechanisms*	*Zuzanna Tracz-Gaszewska (Warsaw)*
09:47-09:50	*Discussion*	
09:50-10:20	*Panel discussion*	

10:20-10:50 Coffee break and poster viewing

SESSION IX – Amyloidosis
Chair: Suzanne Lentzsch (New York)

10:50-10:55	Introduction	Suzanne Lentzsch (New York)
10:55-11:10	Diagnosis, imaging and response assessment in amyloidosis	Ashutosh Wechalekar (London)
11:10-11:15	*Discussion*	
11:15-11:30	Targeted treatment in amyloidosis	Rajshekhar Chakraborty (New York)
11:30-11:35	*Discussion*	
11:35-11:50	Anti-amyloid strategies	Suzanne Lentzsch (New York)
11:50-11:55	*Discussion*	
11:55-12:25	*Panel discussion*	

12:25-12:35 Closing Remarks

MEETING CLOSURE